Unitree Robotics achieves a **629% first-day gain** on the Shanghai STAR Market, marking the largest debut surge of 2024. The listing provides public investors their first exposure to China’s humanoid robotics sector. Vertex Ventures China, an early backer, sees validation of its bet on the company’s growth trajectory.
Vertex Holdings accelerates its capital markets activity with three initial public offerings (IPOs) in June 2026. The platform’s global network drives increased IPO momentum, reflecting strong first-half 2026 performance. Vertex continues expanding its role in facilitating public market listings for companies.
Vertex Ventures China secures at least **$375 million** for its fifth fund targeting investments in China. The Temasek-backed venture capital firm continues expanding its capital base for early-stage and growth-stage opportunities in the region.
Regor Therapeutics secures **$90 million in Series B funding** to advance its pipeline of cancer, immune disorder, and metabolic disease treatments. The clinical-stage biotech company leverages the capital to support drug discovery and development. Investors back its focus on innovative medicines targeting unmet medical needs in oncology and metabolic health.
Feb 2021PR NewswireNews article
Vertex Ventures China
Vertex Ventures China is a venture capital firm investing in early-stage technology and biomedicine companies in China.
